ceftriaxon mip pharma 2 g infuusiokuiva-aine, liuosta varten
mip pharma gmbh - ceftriaxone sodium - infuusiokuiva-aine, liuosta varten - 2 g - keftriaksoni
ganciclovir oresund pharma 500 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos
oresund pharma aps - ganciclovir sodium - kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos - 500 mg - gansikloviiri
pelmeg
mundipharma corporation (ireland) limited - pegfilgrastiimia - neutropenia - immunostimulantit, - vähentää neutropenian kestoa ja kuumeisen neutropenian esiintyvyyden vuoksi kemoterapiaa.
rivastigmine 3m health care ltd
3m health care limited - rivastigmiini - alzheimerin tauti - psychoanaleptics, , antikoliiniesteraasit - lievän tai kohtalaisen vaikean alzheimerin dementian oireellinen hoito.
targiniq 2.5 mg / 1.25 mg depottabletti
mundipharma oy - naloxoni hydrochloridum dihydricum,oxycodoni hydrochloridum - depottabletti - 2.5 mg / 1.25 mg - oksikodoni ja naloksoni
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.
xyrem
ucb pharma ltd - natriumoksibaatti - cataplexy; narcolepsy - muut hermoston huumeet - narkolepsian hoito katapleksiaan aikuispotilailla.
oxycontin 15 mg depottabletti
mundipharma oy - oxycodoni hydrochloridum - depottabletti - 15 mg - oksikodoni
oxycontin 30 mg depottabletti
mundipharma oy - oxycodoni hydrochloridum - depottabletti - 30 mg - oksikodoni
oxycontin 60 mg depottabletti
mundipharma oy - oxycodoni hydrochloridum - depottabletti - 60 mg - oksikodoni